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Background: The national 10-year Development Programme for the Prevention and Care of Diabetes (DEHKO) was
launched in Finland in 2000. The program focused on improving early diagnosis of type 2 diabetes and preventing
diabetes-related complications. The FinDM database was established for epidemiological monitoring of diabetes
and its complications. This study monitors mortality trends among people with diabetes during the DEHKO
programme.
Methods: A database obtained from a compilation of several administrative national health registers was used to
study mortality in people with diabetes in 1998–2007. Relative excess mortality between people with and without
diabetes was analyzed using Poisson regression models.
Results: The number of diabetic people in Finland increased by 66% from 1997 reaching 284 832 in 2007. Like
among non-diabetic people, all-cause mortality decreased in people with diabetes. Overall excess mortality
remained high in people with diabetes; in 2003–2007 RRs in the non-insulin treated was 1.82 for men and 1.95 for
women and in the insulin treated 3.45 and 4.29, and excess coronary heart disease mortality in the insulin treated:
RR was 4.71 in men and 7.80 in women. A striking result was mortality from neoplasms; an increase in mortality
emerged in almost every age group of insulin treated women.
Conclusion: Compared to non-diabetic people our monitoring showed declining excess mortality in non-insulin
treated diabetic people mainly due to a decrease in mortality from cardiovascular diseases. For insulin treated,
relative overall excess mortality remained unchanged and mortality from neoplasms increased among women.
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The contribution of diabetes to the overall burden of
disease has been rapidly increasing in the last twenty years.
The increase in the numbers of diabetic people concerns
both insulin and non-insulin dependent diabetes. This
trend has been shown in Finland [1,2], as in many other
countries [3-6]. While the prevalence of diabetes has
increased worldwide and estimated to increase from 2.8%
in 2000 to 4.4% in 2030 [7], the DIAMOND study showed
an average 3% yearly increase in the incidence of type 1
diabetes in the 1990s worldwide [8].* Correspondence: erja.forssas@thl.fi
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reproduction in any medium, provided the orWhile people with diabetes have earlier been shown to
follow the non-diabetic population in terms of declining
all-cause mortality in Finland [9,10] as well as in Great
Britain and Norway [11,12], previous studies in Finland
have shown that mortality among people with diabetes
remains substantially higher compared to mortality among
people without diabetes. In 1991–1996 the age-standardised
coronary heart disease (CHD) mortality risk among people
with diabetes was sixfold for women and over threefold for
men, compared to persons without diabetes [13]. Excess
mortality due to CHD has also been detected in other
Finnish studies [14,15]. In addition, persons with diabetes
had higher than average mortality for most other causes of
death [14,15]. Similar results have also been observed in
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in all-cause mortality, in CHD mortality and in deaths from
cancer [16-20].
The national 10-year Development Programme for the
Prevention and Care of Diabetes (DEHKO) was launched
in Finland in 2000 [21]. The program focused on improving
early diagnosis of type 2 diabetes and preventing diabetes-
related complications. The FinDM II database based on a
national individual level linkage scheme of health insurance
and care registers was established for epidemiological
monitoring of diabetes and its complications [22]. The
present study monitors changes in mortality among people
with diabetes of varying ages in 1998–2007 in Finland. It
also examines the extent of and changes in excess
mortality according to different causes of death among
insulin-treated and non-insulin-treated people with
diabetes compared to people without diabetes.
Methods
The study population
This study is based on individual-level nationwide register
data on persons with or without diabetes between January
1, 1998 and December 31, 2007 in Finland. Data on persons
diagnosed for diabetes were obtained from the FinDM II
database. FinDM II data linkages received permission to
use study data from different statistical authorities
(National Institute for Health and Welfare, Statistics
Finland, The Social Insurance Institution in Finland).
The data linkages were done by appropriate statistical
authorities as required by Finnish data protection
legislation. The research group received anonymised
data in which individuals were not identifiable. FinDM II
data included individuals with diabetes identified in differ-
ent Finnish health registers: 1) the register of individuals
eligible for elevated reimbursement of medication for
chronic conditions including diabetes, 2) the prescription
register including all reimbursed medicines purchased, 3)
the national hospital discharge registers including 3a) all
inpatient care and 3b) outpatient hospital visits, 4) the
Causes of Death register, and 5) the medical birth register.
The follow-up data were obtained from the same registers.
The Finnish personal identity codes unique to each
resident used in all registers allowed deterministic record
linkage within and between registers.
Individuals were considered to have diabetes since the
first registration of diabetes in any of the registers.
Women with gestational diabetes only were excluded.
The type of diabetes was determined on the basis of
prescription data. Persons with continuous insulin usage
coded according to the ATC system (A10A) and no
purchases of medication intended to increase pancreatic
insulin secretion (sulphonylureas (ATC-code A10BB),
sitagliptin/vildagliptin (A10BH), repaglinide (A10BX02),
nateglinide (A10BX03) or exenatide (A10BX04)) wereconsidered as insulin-treated (ITDM) and the others
as non-insulin-treated (NITDM). The prevalent ITDM
population increased from 33 259 in 1997 (the proportion
of women 44.1%) to 39 575 in 2007 (women 42.1%).
The corresponding increase for the prevalent NITDM
population was from 138 337 (women 55.9%) to 245
257 (women 50.1%).
Tabulated data on Finnish population were obtained
from the national population and causes of death statistics
(yearly mean population and the number of deaths in each
specific (three-digit ICD-10) cause of death stratified by
sex and five-year age groups). The number of people
without diabetes was 4 975 753 in 1997 and 5 015
652 in 2007. Corresponding tabulated data were derived
from the individual level diabetes data stratified additionally
by diabetes type. Numbers for the non-diabetes group were
obtained by subtracting the diabetes group numbers from
the total population numbers.
All analyses were performed using the registered main
cause of death. Three-digit causes of death codes were
classified into ten main categories according to the 10th
revision of the International Statistical Classification of
Diseases and Related Health Problems. All main categories
containing enough cases were included in the analyses.
Also more specific causes of death groups were analyzed, if
there were enough cases and if changes between follow-up
periods were observed.
Statistical analyses
The study data consisted of tabulation of numbers of
deaths and corresponding follow-up time by calendar time
(1-year intervals), age (5-year intervals) at follow-up, dia-
betes status (ITDM, NITDM, no diabetes) and sex for
each specific cause of death.
Mortality rates were modelled using Poisson regression
model in which age and period midpoints were used as
continuous independent variables, number of deaths as
dependent variable, and logarithmic follow-up time in
person years as offset. The functions of age and
period were described using natural (cubic) splines
[23]. Age-specific mortalities were chosen to represent
situation in 2002–2003 and trends in mortality were
examined using rate ratios relative to the year 1998.
To simplify the presentation, mortality was also
studied in 15-year age groups per 1000 person years.
Trends in mortality were scrutinised in two periods
(1998–2002 and 2003–2007). Excess mortality was
calculated as the difference between the mortality
among people with diabetes aged 1–79 and the mortality
among people without diabetes of the same age. The
relative risks of excess mortality in two periods and
the statistical significance of the interaction terms
were obtained from Poisson regression models. The
analyses were performed with the SAS (version 9.2;
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Figure 1 Age-specific mortality (all-cause, circulatory, neoplasms and other diseases) among men in the reference years 2002–2003.
Red is insulin-treated, violet non-insulin-treated and blue non-diabetic.
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software packages.
Results
Age-specific mortality figures in 2002–2003 show that in
all ages diabetic people have increased mortality rates
compared to non-diabetic people (Figures 1 and 2).
Decreasing mortality trends were found in people with and
without diabetes in 1998–2007 except in mortality from
neoplasms among insulin-treated persons (Figure 3 and 4).
An increase in mortality from neoplasms emerged especiallyamong women (Figure 4). From 1998–2002 to 2003–2007,
the all-cause mortality among people with diabetes
decreased in almost all age groups (Additional file 1:
Table S1). In the same time the mortality from
neoplasms increased almost in all age groups between
the study periods. The increase was statistically
significant among women aged 60–74. At the same
time, statistically significant decrease was found in the
mortality from neoplasms among people without diabetes.
A decline in mortality rates from neoplasms and cardio-
vascular diseases (CVDs) was also found during the study
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Figure 2 Age-specific mortality (all-cause, circulatory, neoplasms and other diseases) among women in the reference years 2002–2003.
Red is insulin-treated, violet non-insulin-treated and blue non-diabetic.
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The decrease in CVD mortality was statistically significant
in all age groups among non-insulin-dependent men
with diabetes.
For people with insulin-treated diabetes, the excess
overall mortality in 2003–2007 was more than threefold
among men and fourfold among women compared to
the people without diabetes (Additional file 2: Table S2).
Excess mortality associated with CHD was almost eight-
fold among insulin-treated women and almost fivefold
among men. No decrease in overall excess mortalityfrom 1998–2002 to 2003–2007 was seen. A statistically
significant increase between these two periods was
observed in excess mortality from neoplasms both
among insulin-treated men and women. The increase
was more obvious among women, among whom neoplasm
mortality increased especially with regard to malignancies
of digestive organs, breast and urinary tract, or blood and
lymphatic tissue.
For people with non-insulin-treated diabetes, the
excess overall mortality in 2003–2007 was nearly twofold
both among men and women compared to the people
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Figure 3 Mortality trends among men (all-cause, circulatory, neoplasms and other diseases), relative to the reference year 1998. Red is
insulin-treated, violet non-insulin-treated and blue non-diabetic.
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mortality associated with CHD was over threefold
among non-insulin-treated women and over twofold
among men. A significant decrease in overall excess
mortality from 1998–2002 to 2003–2007 was seen both
among men and women. A statistically significant
decrease between these two periods was mainly observed
in excess mortality from CVD but among men also from
respiratory diseases and diseases of the digestive system.
A slightly, but statistically significant increase in excess
mortality from neoplasm was observed among men.Discussion
We found a decline in the excess overall mortality rate for
non-insulin-treated people with diabetes, especially with
regard to CVD, compared to the people without diabetes
between the periods from 1998–2002 to 2003–2007.
However, the excess overall mortality rate showed no
change for those with insulin-treated diabetes. Further-
more, a statistically significant increase in excess mortality
from cancer was observed.
According to this study the all-cause mortality among
people with diabetes decreased in almost all age groups
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Figure 4 Mortality trends among women (all-cause, circulatory, neoplasms and other diseases), relative to the reference year 1998. Red
is insulin-treated, violet non-insulin-treated and blue non-diabetic.
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Finnish population [10]. Similar development has also been
reported in other countries [11,12]. One explanation might
be that the population with diabetes increases more rapidly
due to more effective screening of type 2 diabetes, which
was emphasized in the national diabetes prevention
program in 2000–2010 in Finland. That might have
brought people earlier to diagnosis and to better care.
Although mortality among people with diabetes decreased,
a significant excess mortality was still found. Some
previous studies have also showed that the rates inall-cause mortality, in CHD mortality and in deaths
from cancer are higher among people with diabetes
than among people without diabetes [14-20].
To our knowledge, the present study is the first to
examine the changes and associations in excess mortality
from specific causes using the whole population together
with all insulin- or non-insulin-treated individuals with
diabetes. Tierney et al. [24] assessed changes in the
excess mortality rate over time in the US for those with
diabetes compared to those without diabetes using
specific causes of deaths. They found that the excess
Forssas et al. BMC Health Services Research 2013, 13:267 Page 7 of 9
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from 1992–1998 to 1999–2003 especially with regard to
CVDs [24]. In spite of different study periods, these findings
were consistent with our results concerning persons with
non-insulin-treated diabetes who normally form the main
part of the population with diabetes.
Insulin-treated people with diabetes
The excess mortality rate for those with insulin-treated
diabetes compared with those without diabetes remained
stable except for increasing excess mortality from
neoplasms.
Contrary to non-insulin-treated people with diabetes,
the excess mortality associated with CVD did not
decrease among insulin-treated people. In 2003–2007,
for example the excess mortality from CHD was almost
eightfold for women and almost fivefold for men with
insulin-treated diabetes compared to people without
diabetes. Our study is in line with earlier results describing
the major impact of diabetes in increasing the risk of
CHD mortality [13-16,18]. We found that excess CHD
mortality was particularly high among insulin-treated
people with diabetes. One reason for higher excess
mortality among insulin-treated compared to non-insulin
-treated individuals might be the longer duration of the
disease. A previous study concerning insulin-dependent
people with diabetes in Finland reported that the relative
mortality, compared with the general population, was
more strongly influenced by duration of diabetes than by
age [25]. Also smoking prevalence might be one reason
for higher CHD mortality among people with diabetes. A
Finnish study conducted in the early 1990’s, discovered
that young adults with diabetes smoked more than
non-diabetic individuals [26].
Among insulin-treated people with diabetes, mortality
from neoplasms increased almost in all age groups
between the study periods. At the same time, mortality
from neoplasms decreased among people without
diabetes and showed also a decreasing trend among
people with non-insulin treated diabetes. The increase
in deaths from cancer was more obvious among
insulin-treated women, among whom mortality increased
especially with regard to cancer of digestive organs, breast
and urinary tract, and lymphoid tissue and blood. Many
studies have indicated that diabetes is associated with an
increased risk of death from malignancies [19,20,27,28].
According to Barone and colleagues [17] there are several
potential explanations for this. First higher insulin levels
may contribute to increased tumor growth [29,30].
Another reason can be that cancer patients with diabetes
might be treated less aggressively than those without
diabetes [31]. Third, patients with diabetes may have
poorer response to cancer treatment, including increased
infection risk and intraoperative mortality [32]. However,it is difficult to explain the most obvious increase in
cancer mortality among women with insulin-treated
diabetes found in this study. Changes in treatment
practices might have influenced in these worse outcomes.
For example, in Sweden during 2006 and 2007, women
using insulin glargine alone had an increased incidence
risk of breast cancer as compared with women using types
of insulin other than insulin glargine [33]. The same
finding was also made in a Scottish study [34]. Further
investigation is needed concerning the increased cancer
mortality among insulin-treated diabetic individuals.
Non-insulin-treated people with diabetes
The excess mortality rate for persons with non-
insulin-treated diabetes compared to those without
diabetes appears to be clearly diminishing. The most
obvious decrease found in excess mortality was that
of CVD mortality. This may mainly have been due to
improved preventive and acute treatment practices
reported in an earlier study by the study group [35].
The proportion of people with diabetes using cholesterol
lowering and antihypertensive drugs increased between
1997 and 2007 in Finland [35]. Another study compared
the use of secondary preventive medication among newly
diagnosed CHD patients with and without diabetes between
1997 and 2002 [36]. It was found that the use of a new class
of antihypertensive drugs, angiotensin II receptor antago-
nists and ACE inhibitors was more common among people
with diabetes compared to people without diabetes. The
use of lipid lowering medication and β-blockers was almost
similar in both groups. Also there has been found improve-
ments in the proportion of people with type 2 diabetes
achieving glycemic target levels in Finland [37]. Similar
development has also been reported in a US study con-
cerning the proportion of people with diagnosed diabetes
achieving glycemic and LDL targets [38].
Our data were based on large national administrative
datasets, namely hospital discharge and cause of
death registers, and reimbursement for medication
and prescription data derived from the Finnish Social
Insurance Institution registries. The reliability of
Finnish health registers has been evaluated good [39].
The reliability of the Finnish Cause of death registers
is also considered good, due to fairly high overall
autopsy rate [40]. Between 1996 and 2007 a medical
or medico-legal autopsy was performed in about 30%
of deaths [10].
A major strength of our study was the use of comprehen-
sive national registers to follow the mortality for all treated
individuals with diabetes in Finland over two five-year time
period. In addition, we were able to compare different treat-
ment groups of people with diabetes. Some methodological
limitations still exist. Individuals treated with diet only were
classified as non-diabetic individuals, if diabetes was not
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treated with diet only are mainly among people aged over
65 [41]. The different treatment groups were not identified
from the medical records but from medication and hospital
discharge registers. However, those recorded insulin-treated
have for the most type 1 diabetes and those with
non-insulin treated type 2 diabetes. Despite these limita-
tions this material is unique. Our data encompass the whole
population of a country; all diabetic individuals receiving
medication have been identified, and all cause of deaths in
1998–2007 have been registered and analyzed according to
sex and diabetes treatment groups.
Conclusions
The present study indicates that excess mortality has
remained high among individuals with diabetes. Mortality
among people with non-insulin-treated diabetes compared
to the non-diabetic population has decreased especially
with regard to CVDs, whereas no decrease among insulin-
treated were seen. Among people with insulin-treated
diabetes, significant increase was observed in excess mor-
tality from cancer among women. Further investigation is
needed concerning the increased cancer mortality among
insulin-treated diabetic individuals.
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